Oral and inhaled biologics are gaining R&D investment due to patient acceptance and potential for home administration, with ...
In episode 27, Christopher Hopkins, PhD; Omkar Kawalekar, PhD; Barnaby Pickering; and Jerry Rosenbaum, MD, go behind the ...
At CPHI and AAPS, Ashland plans to detail the impacts of its advanced excipients: ultra-low nitrite materials curb ...
Major pharmaceutical investments in the United States are expanding API, capsule, and packaging capacity, enhancing supply chain resilience and supporting domestic drug production.
The oncology pipeline is marked by heterogeneity and complexity (1). Moving forward, pharmaceutical scientists must navigate the intersection of advanced biology, next-generation delivery platforms, ...
The first needle-free adrenaline treatment launches in the UK, validating non-invasive delivery with real-world data ...
Advanced biotech equipment, driven by R&D investment and personalized medicine, is essential for scalable drug production and ...
M&A favors late-stage assets, obesity deals surge, AI accelerates manufacturing, and policy drives strategic US facility ...
As the conference approaches, scientists are reviewing new technologies that enhance manufacturing process control, product ...
This article outlines common CMC problems that are obstacles that steal momentum and create costly detours in the development ...
AstraZeneca’s $4.5 billion investment in Virginia expands its US drug manufacturing footprint, creating 3600 jobs and ...
ICE Pharma will present its bile acid-derived innovations and sustainability strategies at CPHI Frankfurt 2025. The company's ...